Finnish-US firm Oura launches world’s smallest smart ring as it heads towards IPO

Oura launched its fifth-generation Ring 5, 40% smaller than the Ring 4 and priced from $399 plus a $5.99 monthly subscription, as it prepares for an IPO later this year. The company says it has 5 million paying subscribers, 5.5 million rings sold across 150 countries, and revenue that rose fourfold over two years to $1bn in 2025, supporting an $11bn valuation. The article also highlights expansion into proactive health features, including blood pressure and sleep-breathing alerts and GLP-1 tracking.

Analysis

Oura’s real edge is not hardware miniaturization; it is subscription lock-in around a high-frequency health dataset. A 23.5-hour daily wear pattern means the company is behaving less like a gadget maker and more like a consumer health telemetry platform, which should compress the gap between product usage and monetization over the next 12-24 months. That creates a favorable dynamic for adjacent categories that benefit from validated, longitudinal biometrics: sleep tech, at-home diagnostics, women’s health, and employer wellness, while putting pressure on generic smartwatch vendors whose engagement is broader but shallower.

The second-order winner is likely the ecosystem around health data interpretation, not the ring itself. As Oura pushes into predictive alerts and medication-related insights, it moves closer to a regulated health-adjacent workflow, which raises the switching costs for users and increases the value of insurance, provider, and research partnerships. The risk is that this expansion invites scrutiny around medical claims, data privacy, and liability if alerts become clinically misleading; any regulatory drag would matter over months, not days.

The IPO setup looks more attractive on narrative than on near-term economics. A $11B valuation against $1B revenue is reasonable only if retention stays high and subscription ARPU expands; if growth decelerates post-launch or app engagement normalizes, multiple compression could be swift. The market may be underestimating how much of the upside has already been pulled forward by private-market enthusiasm, making a public listing vulnerable to a classic “great product, rich price” reset.

From a competitive standpoint, Apple is not the clean loser here because it already owns the wrist and health stack; the better short is lower-moat wearable and smart-accessory names that rely on form factor rather than ecosystem depth. The more contrarian take is that Oura’s best long-term enemy is success itself: if it becomes too health-like, it may lose some of the consumer delicacy that made the ring category appealing. That tension between wellness brand and quasi-medical platform is where the next re-rating or de-rating will come from.

Key Decisions for Investors

• Avoid chasing the IPO at the first print; wait 6-8 weeks post-listing for subscription retention and guidance clarity. If secondary trading opens at a premium >25% to implied IPO valuation, expect multiple compression and use any gap-up to fade.
• Pair trade: long HIMS / short a basket of hardware-led wearables and accessory companies with weaker software monetization. Oura validates demand for continuous, personalized health engagement, but the winners should be those with recurring revenue, not device margin alone.
• Selective long on consumer health-data platforms with strong retention economics over 6-12 months. Use a basket approach rather than a single-name bet, since the key variable is whether Oura proves that wearable data can support higher subscription ARPU across adjacent categories.
• Short-term hedge: buy downside protection on any listed wearable peers into the IPO window. If Oura IPOs well, it raises the bar for growth durability across the cohort; if it disappoints, sentiment can re-rate the entire category downward quickly.
• Monitor regulatory headlines for privacy or medical-claim scrutiny over the next 3-9 months; if those intensify, expect a de-rating in the health-wearables complex and trim exposure aggressively.